Minerva Neurosciences | NERV - Operating Expenses


Minerva Neurosciences reported $4.52M in Operating Expenses for its fiscal quarter ending in December of 2024.





Operating Expenses Change Date
Acadia Pharmaceuticals USD 272.68M 6.08M Mar/2026
Adma Biologics USD 76.41M 6.8M Dec/2025
ALKERMES USD 1.75B 1.43B Mar/2026
Alterity Therapeutics Limited AUD 8.67M 893.38K Dec/2025
AstraZeneca USD 8.18B 4.35B Mar/2026
BioCryst Pharmaceuticals USD -553.84M 700.01M Mar/2026
Bristol-Myers Squibb USD 20.07B 11.77B Mar/2026
Cipla INR 59.27B 1.71B Mar/2026
Clal Biotechnology ILS 5.15M 9.47M Dec/2022
Compugen USD 11.29M 1.51M Dec/2025
CSL USD 5.7B 2.82B Dec/2025
Eli Lilly USD 10.02B 285M Mar/2026
Esperion Therapeutics USD 83.21M 14.06M Dec/2025
GlaxoSmithKline GBP 5.34B 1.85B Mar/2026
Grifols EUR 1.99B 217.4M Dec/2025
Halozyme Therapeutics USD 192.19M 18.88M Mar/2026
Ionis Pharmaceuticals USD 364M 54M Mar/2026
J&J USD 17.44B 1.53B Mar/2026
Merck USD 18.17B 8.01B Mar/2026
Minerva Neurosciences USD 4.52M 155.46K Dec/2024
Neurocrine Biosciences USD 599.9M 22.3M Mar/2026
Novartis USD 9.29B 507M Mar/2026
Novavax USD 126.2M 23.62M Dec/2025
Pfizer USD 90.1B 77.19B Mar/2026
Roche Holding CHF 21.01B 10.84B Dec/2025
Sanofi EUR 9.31B 1.2B Mar/2026
Takeda JPY 1.11T 85.29B Mar/2026
Vanda Pharmaceuticals USD -1.14B 1.6B Dec/2025